Home Economics 23andMe Eyes $1.7B Valuation With $200M Round

23andMe Eyes $1.7B Valuation With $200M Round

Genetics company 23andMe is in the process of raising about $200 million, as first reported by TechCrunch. The funding will reportedly be led by Sequoia and come with a $1.7 billion valuation. 23andMe offers genetic services that provide users with information about their ancestry and personal health.

News of the round comes about five months after 23andMe scored a big win for one of its products, with the US Food and Drug Administration approving a saliva-based test that assesses a person’s genetic risk for Alzheimer’s, Parkinson’s and eight other diseases. Since it was founded in 2006, the Bay Area biotech has raised hundreds of millions—but co-founder and CEO Anne Wojcicki is said to be in no rush to IPO. Here’s a look at the company’s equity funding history:

May 2007: $9M funding | $45M valuation

Dec. 2009: $27.8M | $138.9M

Jan. 2011: $31M | $179M

Dec. 2012: $58M | $288.7M

Oct. 2015: $115M | $1.1B

Want more info on 23andMe? Check out its free profile.

Article by PitchBook


A Premium Investing Resource
An Absurdly Low Price

“ValueWalk provides an invaluable service—bringing together the best and most important commentary in the world of value investing, all in one place.”

Maybe THAT kind of insight makes it clear that ValueWalk Premium is worth another look.

It seems like a pretty easy decision.

One that will help make bigger, better decisions in the future.

Exit mobile version